Karyopharm Therapeutics (NASDAQ: KPTI) reported Q4 EPS of ($0.81), versus ($0.79) reported last year.

Based on current operating plans, Karyopharm expects that its existing cash and cash equivalents will fund its research and development programs and operations into the middle of 2018, including advancing the four later-stage clinical studies to their next data inflection points. Karyopharm expects to end 2016 with at least $120 million in cash, cash equivalents and investments.

For earnings history and earnings-related data on Karyopharm Therapeutics (KPTI) click here.